🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Xspray Pharma AB (publ) (STO:XSPRAY)
Sweden flag Sweden · Delayed Price · Currency is SEK
10.18
-0.30 (-2.86%)
Nov 20, 2026, 5:29 PM CET

Xspray Pharma AB Earnings Call Transcripts

Fiscal Year 2026

  • Lucamzi is preparing for a mid-2027 U.S. launch, while Xdivane targets an FDA submission after a Q2 2027 trial readout and a day-one post-patent launch. Restructuring and partner-led launches support a path toward positive cash flow.

  • FDA announcement

    The FDA's CRL for Dasynoc centers on facility status and a request for more commercial-scale batch data, with no new clinical or product quality concerns. Batch work is being accelerated for a 2026 resubmission, and commercialization plans remain on track pending regulatory clearance.

Fiscal Year 2023

Fiscal Year 2021